Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

NANot yet recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Carcinoma, HepatocellularNeoplasms, Glandular and EpithelialAdenocarcinomaDigestive System NeoplasmsLiver Neoplasms
Interventions
DEVICE

Multimodal Thermal Therapy

The high-burden tumor is identified as the target lesion for treatment. A pre-treatment biopsy of the target lesion is performed to obtain tumor tissue. Multimodal ablation therapy of the target lesion is conducted under CT guidance. The treatment procedure follows the tumor ablation protocol using the multimodal therapy radiofrequency temperature-controlled mode.

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT06794073 - Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study | Biotech Hunter | Biotech Hunter